Eva Mischak-Weissinger
Overview
Explore the profile of Eva Mischak-Weissinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basilio-Queiros D, Mischak-Weissinger E
Front Immunol
. 2023 Jun;
14:1172437.
PMID: 37275911
Natural Killer (NK) cells have come a long way since their first description in the 1970's. The most recent reports of their adaptive-like behavior changed the way the immune system...
2.
Crossland R, Norden J, Ghimire S, Juric M, Pearce K, Lendrem C, et al.
Front Immunol
. 2021 Apr;
12:639171.
PMID: 33790910
Acute graft vs. host disease (aGvHD) is a frequent complication following allogeneic haematopoeitic transplantation (HSCT). Despite recent advances, there are no universally accepted biomarkers to determine development of aGvHD. MicroRNAs...
3.
Verma K, Ogonek J, Varanasi P, Luther S, Bunting I, Thomay K, et al.
PLoS One
. 2017 May;
12(5):e0177405.
PMID: 28481945
End-stage differentiation of antigen-specific T-cells may precede loss of immune responses against e.g. viral infections after allogeneic stem cell transplantation (SCT). Antigen-specific CD8+ T-cells detected by HLA/peptide multimers largely comprise...
4.
Hage E, Wilkie G, Linnenweber-Held S, Dhingra A, Suarez N, Schmidt J, et al.
J Infect Dis
. 2017 Apr;
215(11):1673-1683.
PMID: 28368496
Background: Advances in next-generation sequencing (NGS) technologies allow comprehensive studies of genetic diversity over the entire genome of human cytomegalovirus (HCMV), a significant pathogen for immunocompromised individuals. Methods: Next-generation sequencing...
5.
Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al.
PLoS Pathog
. 2016 Dec;
12(12):e1006015.
PMID: 27907183
Development of an effective vaccine against human cytomegalovirus (HCMV) is a need of utmost medical importance. Generally, it is believed that a live attenuated vaccine would best provide protective immunity...
6.
Qesari M, Richter A, Ogonek J, Mischak-Weissinger E, Wang X, Dickinson A
Transplantation
. 2016 May;
100(11):2352-2361.
PMID: 27152919
Background: Graft-versus-host (GvH) disease (GvHD) remains a serious concern for patients undergoing antiviral cellular therapy. Despite the major improvements in cellular immunotherapy, the immunogenicity of virus-specific T cells has not...
7.
Pearce K, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, et al.
Cytotherapy
. 2013 Oct;
16(3):289-97.
PMID: 24113428
Background Aims: Advanced therapy medicinal products (ATMP) are gene therapy, somatic cell therapy or tissue-engineered products regulated under (EC) No. 1394/2007 to ensure their free movement within the European Union...
8.
Sukdolak C, Tischer S, Dieks D, Figueiredo C, Goudeva L, Heuft H, et al.
Biol Blood Marrow Transplant
. 2013 Jul;
19(10):1480-92.
PMID: 23891747
Adoptive immunotherapy with virus-specific T lymphocytes can efficiently reconstitute antiviral immunity against cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) without causing acute toxicity or increasing the risk of graft-versus-host...
9.
Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C, et al.
Haematologica
. 2012 Sep;
97(9):e34-5.
PMID: 22952334
No abstract available.
10.
Salguero G, Sundarasetty B, Borchers S, Wedekind D, Eiz-Vesper B, Velaga S, et al.
Hum Gene Ther
. 2011 May;
22(10):1209-24.
PMID: 21574869
Dendritic cell (DC)-based immunization is a potent strategy to direct prompt and durable immune responses against viral reactivations after transplantations. Here, we show that overnight lentiviral vector (LV) gene transfer...